Chordate Medical's CEO Anders Weilandt and CSO Jan Hermansson are currently in Barcelona at the European Headache Congress to present Ozilia to the gathered migraine and headache industry. The congress is attended by 2,200 delegates from both Europe and other markets, and the interest in Ozilia is continuing to grow.
"During the first days, we have generated an impressive number of leads from stakeholders who clearly indicate buying interest. Awareness of Ozilia is beginning to establish itself at very satisfactory levels. We cannot currently serve all interested stakeholders since some markets outside the EU and GCC require product registration – but the need for Ozilia as a drug-free treatment alternative for migraine is evident," says Anders Weilandt.
Chordate is in Barcelona together with the company's Italian distributor Vedise Hospital S.p.A, who will bring home a number of leads. EHC is one of the foremost meeting places for the headache and migraine sector, with representatives from both research and industry from around the world.
"In addition to significant interest from the healthcare sector, we also notice that the exploratory interest from the pharmaceutical industry has increased significantly compared to previous congresses where we have participated. It is evident that they both want to learn more and understand what we are doing."
For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.
Image Attachments
Chordate På EHC